Tumor Board NGS Recap

Cancer doctors at the Miami Precision Medicine meeting used next-generation sequencing — a broad DNA readout of a tumor — to turn mutation findings into treatment choices across lung, brain and sarcoma cases. (miami.cloud-cme.com) The University of Miami’s 2nd Biennial Miami Precision Medicine Conference ran May 4-5, 2024, and its program said an interdisciplinary molecular tumor board would use germline and genomic alterations to select targeted treatments and discuss relevant clinical trials. (news.med.miami.edu) A molecular tumor board is a case conference for difficult cancers: oncologists, pathologists, radiologists and other specialists review sequencing results together and decide whether a mutation is useful enough to guide therapy. A 2024 review in *memo* said these boards were built to translate complex molecular test results into treatment recommendations. (springer.com) Next-generation sequencing works like reading many pages of a tumor’s instruction manual at once instead of checking one typo at a time. The Miami meeting materials listed sequencing, molecular pathways and liquid biopsy among the core topics for clinicians. (news.med.miami.edu) That matters in lung cancer because the drug often depends on the exact DNA change, not just the organ where the cancer started. The Food and Drug Administration approved repotrectinib on November 15, 2023 for locally advanced or metastatic ROS1-positive non-small cell lung cancer, including patients who had already received a ROS1 inhibitor. (fda.gov) It matters in central nervous system tumors too, where molecular testing now shapes diagnosis as well as treatment. The National Comprehensive Cancer Network says its Central Nervous System Cancers Guidelines, version 3.2025, cover adult glioma categories defined by markers such as IDH mutation and 1p/19q codeletion. (nccn.org) Some targeted drugs now cut across tumor types when the same mutation appears in different organs. The Food and Drug Administration granted accelerated approval on June 22, 2022 to dabrafenib plus trametinib for unresectable or metastatic solid tumors with BRAF V600E mutations, and approved larotrectinib for solid tumors with NTRK gene fusions in 2018 before Bayer announced full approval on April 10, 2025. (fda.gov 1) (fda.gov 2) (bayer.com) Sarcoma is one of the diseases where that approach can matter because some tumors carry rare fusions or mutations that standard pathology can miss. A 2025 *JCO Precision Oncology* study said international guidelines recommend next-generation sequencing for several cancers, including soft-tissue sarcoma, and reported that 1,813 cases were discussed at one molecular tumor board, with 458 considered potentially eligible for molecularly targeted agents and 117 actually starting one. (ascopubs.org) Reviews in *Nature Reviews Clinical Oncology* and *memo* describe the same bottleneck the Miami panel was built to address: sequencing can find many alterations, but their meaning changes as trial data and drug approvals change. Those reviews say molecular tumor boards increasingly match patients to approved drugs or clinical trials, while also facing limits in funding, expertise and access. (nature.com) (springer.com) The Miami recap’s main point was practical rather than theoretical: sequencing only changes care when a team can decide which mutation is actionable, which drug fits, and whether a patient can actually get it. That is the work molecular tumor boards were created to do. (miami.cloud-cme.com) (nature.com)